Making the switch from autologous to allogeneic cell therapy
September 09, 2022
Elena Matsa & Andy Holt
To set the scene, could you firstly tell me a bit about your backgrounds, and your current work?
What role do you predict induced pluripotent stem cells (iPSCs) will play in the future of cell therapy?
What are the key benefits of autologous versus allogeneic cell therapies?
What do you see as the biggest obstacles to successful iPSC-based allogeneic cell therapy development – and how can they be addressed?
What are the most important considerations for developing a successful cell therapy manufacturing process?
What is your key advice for making the change from autologous to allogeneic cell therapy development a practical reality?